119 results on '"Rieder, Florian"'
Search Results
2. Results of the 4th Scientific Workshop of the ECCO (Group II): Markers of intestinal fibrosis in inflammatory bowel disease
3. Safety and efficacy of endoscopic dilation for primary and anastomotic Crohn's disease strictures
4. Results of the 2nd Scientific Workshop of the ECCO (III): Basic mechanisms of intestinal healing
5. Intestinal fibrosis in inflammatory bowel disease — Current knowledge and future perspectives
6. THE PATHOGENIC ROLE OF MICROBIAL TRIMETHYLAMINE IN IBD ASSOCIATED INTESTINAL FIBROSIS.
7. The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease.
8. Mo1784 HIGH-RESOLUTION IMPEDANCE PLANIMETRY CHARACTERIZES THE MECHANICAL FEATURES OF CROHN'S DISEASE STRICTURES – IMPLICATIONS FOR PATIENT STRATIFICATION.
9. Mo1763 POSTOPERATIVE RECURRENCE IN INFLAMMATORY BOWEL DISEASE ASSOCIATED PERMANENT END ILEOSTOMY: A SYSTEMATIC REVIEW.
10. Su1770 EFFECT OF RISANKIZUMAB ON EARLY SYMPTOMS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF THE INSPIRE INDUCTION STUDY.
11. Sa1881 MICROBIAL TRIMETHYLAMINE EXERTS PROFIBROTIC PROPERTIES IN IBD - IMPLICATIONS FOR NOVEL ANTI-FIBROTIC THERAPIES.
12. Sa1267 ESOPHAGEAL LUMINAL DIAMETER IS ASSOCIATED WITH DYSPHAGIA IN EOSINOPHILIC ESOPHAGITIS: IMPLICATIONS FOR ENDOSCOPIC DILATION THERAPY.
13. Sa1199 CONDENSINS ARE UPREGULATED IN CROHN'S DISEASE PATIENT ILEAL EPITHELIAL CELLS AND PROMOTE INTESTINAL PERMEABILITY.
14. 1142 INTEGRIN INHIBITION REDUCES PROFIBROTIC RESPONSES IN CROHN'S DISEASE (CD) HUMAN INTESTINAL MYOFIBROBLASTS IN VITRO AND AMELIORATES EXPERIMENTAL INTESTINAL FIBROSIS IN VIVO - A POTENTIAL NOVEL APPROACH TO CD STRICTURE THERAPY.
15. 1095 EXHALED BREATH ANALYSIS OF VOLATILE ORGANIC COMPOUNDS IS ASSOCIATED WITH LUMINAL DISEASE ACTIVITY IN PATIENTS WITH ULCERATIVE COLITIS.
16. 963 THE BREATH METABOLOME SIGNATURE IS LINKED WITH DIAGNOSIS OF EOSINOPHILIC ESOPHAGITIS: PILOT STUDY ASSESSING EXHALED VOLATILE ORGANIC COMPOUNDS.
17. 760 TRANSGLUTAMINASE 2 IS ELEVATED IN CROHN'S DISEASE ASSOCIATED STRICTURES AND EXERTS PROFIBROTIC ACTIVITIES IN MYOFIBROBLASTS AND EXPERIMENTAL INTESTINAL FIBROSIS.
18. 173 DUAL ACTIVATION OF GCGR/GLP1R SIGNALING AMELIORATES INTESTINAL FIBROSIS VIA METABOLIC REGULATION OF HISTONE H3K9 LACTYLATION IN EPITHELIAL CELLS.
19. Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel Disease.
20. Routine rescreening for latent tuberculosis has low utility in patients with chronic immune-mediated inflammatory diseases treated with biologics: A single-center, retrospective cohort study.
21. An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials.
22. Not Hard to Swallow—Understanding Endothelial-Fibroblast Crosstalk in Eosinophilic Esophagitis.
23. Quantitative Analysis of Patellar Tendon After Total Knee Arthroplasty Using Echo Intensity: A Nonrandomized Controlled Trial of Alpine Skiing.
24. Selective deletion of MyD88 signaling in α-SMA positive cells ameliorates experimental intestinal fibrosis via post-transcriptional regulation.
25. Intestinal proteomic analysis of a novel non-human primate model of experimental colitis reveals signatures of mitochondrial and metabolic dysfunction.
26. Pathogenesis of fibrostenosing Crohn's disease.
27. Treatments for Crohn's Disease–Associated Bowel Damage: A Systematic Review.
28. The emerging role of histologic disease activity assessment in ulcerative colitis.
29. Tu1718 A PHASE 1B STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS AND CLINICAL EFFICACY OF THE NUCLEOTIDEBINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS.
30. Tu1710 ADDITIONAL RISANKIZUMAB TREATMENT IS EFFECTIVE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO DID NOT ACHIEVE CDAI CLINICAL RESPONSE WITH THE INITIAL 12-WEEK INDUCTION TREATMENT: RESULTS FROM THE ADVANCE, MOTIVATE, AND...
31. Tu1256 USTEKINUMAB FOR THE TREATMENT OF SYMPTOMATIC SMALL BOWEL STRICTURING CROHN'S DISEASE - RESULTS FROM AN INTERNATIONAL MULTICENTER COHORT STUDY.
32. Tu1249 CROHN'S DISEASE INTESTINAL MUSCLE CELL DERIVED FIBRONECTIN PROMOTES PROLIFERATION OF INTESTINAL MUSCULARIS PROPRIA MUSCLE CELLS – A NOVEL LINK BETWEEN MUSCLE FIBROSIS AND PROLIFERATION IN STRICTURING CROHN'S DISEASE.
33. Tu1246 CROHN'S DISEASE STRICTURE MATRISOME ANALYSIS REVEALS THE ANTI-FIBROTIC ACTIVITY OF MILK-FAT GLOBULE-EPIDERMAL GROWTH FACTOR 8 (MFGE8).
34. Mo1735 EARLY HISTO-ENDOSCOPIC RESPONSE AT WEEK 12 PREDICTS CLINICAL OUTCOMES AT WEEK 52 WITH MIRIKIZUMAB IN ULCERATIVE COLITIS LUCENT TRIALS.
35. Mo1726 INTESTINAL ULTRASOUND OF FIBROSTENOTIC CROHN'S DISEASE CORRELATES WITH HISTOLOGY OF SURGICALLY RESECTED STRICTURES.
36. MFGE8 links absorption of dietary fatty acids with catabolism of enterocyte lipid stores through HNF4γ-dependent transcription of CES enzymes.
37. Cooling Down the Hot Potato: Anti-Interleukin 36 Therapy Prevents and Treats Experimental Intestinal Fibrosis.
38. Test Characteristics of Cross-sectional Imaging and Concordance With Endoscopy in Postoperative Crohn's Disease.
39. ROCKing the Field of Intestinal Fibrosis or Between a ROCK and a Hard Place?
40. Mo1563: POST-OPERATIVE IMMUNOSUPPRESSIVE THERAPY FOLLOWING ILEAL POUCH ANAL ANASTOMOSIS CREATION: AN ASSESSMENT USING THE TRINETX COHORT.
41. Sa1591: INTRAABDOMINAL SEPTIC COMPLICATIONS AFTER ILEOCOLIC RESECTION INCREASES ENDOSCOPIC POSTOPERATIVE CROHN'S DISEASE RECURRENCE.
42. 720: EARLY INITIATION OF ANTI-TUMOR NECROSIS FACTOR THERAPY REDUCES POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE FOLLOWING ILEOCECAL RESECTION.
43. 719: POSTOPERATIVE CROHN'S DISEASE RECURRENCE RISK AND OPTIMAL BIOLOGIC TIMING AFTER TEMPORARY DIVERSION FOLLOWING ILEOCECAL RESECTION.
44. 587: EPIDEMIOLOGY AND RISK FACTORS ASSOCIATED WITH MALE SEXUAL DYSFUNCTION IN PATIENTS WITH ILEO-ANAL POUCH ANASTOMOSIS.
45. 456: CHRONOLOGIC AGE IS NOT ASSOCIATED WITH RISK OF POSTOPERATIVE RECURRENCE IN CROHN'S DISEASE.
46. 401: ANASTOMOTIC CONFIGURATION AND DIVERTING OSTOMY DOES NOT INCREASE THE RISK OF POSTOPERATIVE ANASTOMOTIC STRICTURES IN CROHN'S DISEASE.
47. Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review.
48. Patients With Low Drug Levels or Antibodies to a Prior Anti–Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti–Tumor Necrosis Factor.
49. Gastroesophageal Reflux Disease–Associated Esophagitis Induces Endogenous Cytokine Production Leading to Motor Abnormalities.
50. Biologic agents and small molecules – mechanism of action.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.